Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bronchodilators

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44350   clinical trials with a EudraCT protocol, of which   7377   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    155 result(s) found for: Bronchodilators. Displaying page 8 of 8.
    « Previous 1  2  3  4  5  6  7  8 
    EudraCT Number: 2020-002023-11 Sponsor Protocol Number: 53718678RSV3001 Start Date*: 2021-02-16
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rilematovir in Infants and Children (≥28 Days to ≤5 Years of Age) and Subsequently in Neonates (...
    Medical condition: Respiratory Syncytial Virus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BG (Completed) DE (Prematurely Ended) SE (Completed) CZ (Completed) HU (Completed) BE (Completed) PL (Completed) Outside EU/EEA EE (Completed) LV (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001149-25 Sponsor Protocol Number: FSS-AS-301 Start Date*: 2014-11-07
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A 12-Week, Double-Blinded, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone/ Salmeterol Multidose Dry Powder Inhaler i...
    Medical condition: Persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2007-000548-29 Sponsor Protocol Number: ADA103575 Start Date*: 2007-05-04
    Sponsor Name:GlaxoSmithKline R&D
    Full Title: A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg OD versus Mont...
    Medical condition: Persistent asthma and seasonal allergic rhinitis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    9.1 10039776 Seasonal allergic rhinitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: EE (Completed) FI (Prematurely Ended) PL (Ongoing)
    Trial results: View results
    EudraCT Number: 2010-020841-29 Sponsor Protocol Number: ADAPT Start Date*: 2011-07-07
    Sponsor Name:King`s College London [...]
    1. King`s College London
    2. Guy`s & St Thomas` NHS Foundation Trust
    Full Title: The role of anti-IgE (omalizumab) in the management of severe recalcitrant paediatric atopic eczema
    Medical condition: Severe eczema in children
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10003641 Atopic eczema LLT
    19.0 100000004858 10014189 Eczema allergic atopic LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-003717-11 Sponsor Protocol Number: GECP22/02 Start Date*: 2023-04-17
    Sponsor Name:Fundación GECP
    Full Title: Phase II clinical trial of Neo-adjuvant chemo/immunotherapy followed by adjuvant treatment depending on the resection status for the treatment of NSCLC patients diagnosed with pancoast tumor. A mul...
    Medical condition: Resectable Non-small cell lung cancer Pancoast tumor
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033572 Pancoast's tumour PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001051-19 Sponsor Protocol Number: CQAB149B2217 Start Date*: 2007-07-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A double-blind, randomized, cross-over, placebo-controlled, 2-part study to compare the effect of exercise and high-dose salbutamol on maximal heart-rate in patients with COPD following therapeutic...
    Medical condition: COPD (chronic Obstructive Pulmonary Disease)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000192-13 Sponsor Protocol Number: COLO/DPI/02/11 Start Date*: 2011-04-28
    Sponsor Name:Forest Laboratories UK Ltd.
    Full Title: A 7-day open-label pharmacokinetic study to investigate the systemic absorption of colistimethate sodium after inhalation of dry powder colistimethate sodium for inhalation (Colobreathe® 125mg) in ...
    Medical condition: cystic fibrosis subjects with chronic pulmonary infection with Pseudomonas aeruginosa
    Disease: Version SOC Term Classification Code Term Level
    13.1 10010331 - Congenital, familial and genetic disorders 10011763 Cystic fibrosis lung PT
    13.1 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004759-37 Sponsor Protocol Number: CCD-1107-PR-0067 Start Date*: 2012-02-29
    Sponsor Name:Chiesi Farmaceutici SpA
    Full Title: RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED, 3-ARM PARALLEL GROUP, MULTI-NATIONAL, MULTI-CENTRE STUDY TO EVALUATE THE CARDIAC SAFETY OF TWO DOSES OF GLYCOPYRROLATE BROMIDE (25µG AND 50µG BID) DELIV...
    Medical condition: Moderate and severe COPD
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) GB (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-000923-25 Sponsor Protocol Number: FSS-AS-30017 Start Date*: 2014-11-07
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A 12-Week, Double-Blinded, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone/ Salmeterol Multidose Dry Powder Inhaler i...
    Medical condition: Persistent Asthma
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2022-002677-29 Sponsor Protocol Number: 4739 Start Date*: 2023-01-11
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI FERRARA
    Full Title: Correlating Inflammatory Values of FEno, SymToms, SpuTum and Lung Function in Asthma
    Medical condition: Asthma, a chronic inflammatory disease of the airways, is characterized by a variability of symptoms that can evolve in an acute and sometimes severe form. Treatment of asthma involves daily treatm...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064823 Asthmatic crisis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-002828-37 Sponsor Protocol Number: D2912C00003 Start Date*: 2021-09-13
    Sponsor Name:AstraZeneca AB
    Full Title: A Two-part Phase IIa Randomised, Double-blind, Placebo-controlled, Dose ranging, Multi centre Study to Assess Efficacy and Safety of Inhaled AZD1402 Administered as a Dry Powder Twice Daily for Fou...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004966-16 Sponsor Protocol Number: CQVA149A2318 Start Date*: 2013-02-27
    Sponsor Name:Novartis Pharma AG
    Full Title: A 52-week treatment, multi-center, randomized, double-blind, double-dummy, parallel-group, active controlled study to compare the effect of QVA149 (indacaterol maleate / glycopyrronium bromide) wit...
    Medical condition: subjects with moderate to very severe COPD
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) SE (Completed) ES (Completed) AT (Completed) LT (Completed) NL (Completed) CZ (Completed) FI (Completed) DE (Completed) BE (Completed) IS (Completed) IT (Completed) PT (Completed) NO (Completed) PL (Completed) EE (Completed) DK (Completed) BG (Completed) LV (Completed) GR (Completed) GB (Completed) LU (Completed)
    Trial results: View results
    EudraCT Number: 2012-000520-18 Sponsor Protocol Number: CQMF149E2203 Start Date*: 2012-10-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, placebo controlled, 12-week treatment, parallel-group study to assess the efficacy, safety and pharmacokinetics of indacaterol acetate (75 and 150 μg o.d.) ...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    15.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SK (Completed) DE (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-002298-69 Sponsor Protocol Number: CQGE031B2201 Start Date*: 2013-01-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Multi-Center, Randomized, Double Blind, Placebo and Active-Controlled study with exploratory dose-ranging, to investigate the efficacy and safety of 16 weeks treatment with subcutaneous QGE031 in...
    Medical condition: asthma
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SK (Completed) CZ (Completed) PT (Completed) GB (Completed) HU (Completed) IT (Completed) DE (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001540-56 Sponsor Protocol Number: 208657 Start Date*: 2019-08-18
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A multi-center, randomized, double-blind, parallel-group, placebo controlled study of mepolizumab 100 mg SC as add-on treatment in participants with COPD experiencing frequent exacerbations and cha...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) HU (Completed) ES (Ongoing) NL (Completed) DK (Completed) BE (Completed) DE (Completed) SE (Completed) IE (Completed) IT (Completed) GR (Completed) AT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 18 12:27:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA